Interventions of Interest:

  • sotatercept (Merck & Co)

Pulmonary arterial hypertension (PAH) is a rare, progressive disease characterized by thickening of the walls of the pulmonary arteries that carry blood from the right side of the heart to the lungs, leading to increased pulmonary vascular resistance. The increased pressure in the pulmonary arteries makes it more difficult for the heart to pump blood to the lungs and leads to debilitating symptoms such as shortness of breath (particularly with exertion), chest pain, fatigue, dizziness, syncope, and leg edema.

For questions please contact Yamaya Jean, Program Manager, at yjean@icer.org.

View the Key Stakeholder List.